ImQuest BioSciences

Executive Summary

ImQuest BioSciences is a preclinical contract research organization (CRO) specializing in infectious disease and antibody research. Founded in 2004 and based in Frederick, Maryland, the company offers a range of services to evaluate novel compounds against viruses, bacteria, cancer, and inflammatory diseases. Its client base includes pharmaceutical and biotechnology companies, as well as academic investigators. As a service provider, ImQuest benefits from the growing outsourcing trend in drug development, but its growth is inherently tied to the R&D spending of its clients and the broader biotech funding environment. The company operates at the preclinical stage and has not disclosed specific financial or pipeline details, making it a low-visibility entity. However, its niche expertise in infectious disease positions it well for opportunities arising from pandemic preparedness and antimicrobial resistance initiatives.

Upcoming Catalysts (preview)

• Q4 2026Expansion of BSL-3 laboratory capacity60% success
• Q3 2026Major contract award for antiviral preclinical services50% success
• Q1 2027Partnership with a large pharma for antibody discovery platform40% success